Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
Identifieur interne : 000413 ( PubMed/Curation ); précédent : 000412; suivant : 000414Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
Auteurs : Yuko Koshimori [Canada] ; Ji-Hyun Ko [Canada] ; Romina Mizrahi [Canada] ; Pablo Rusjan [Canada] ; Rostom Mabrouk [Canada] ; Mark F. Jacobs [Canada] ; Leigh Christopher [Canada] ; Clement Hamani [Canada] ; Anthony E. Lang [Canada] ; Alan A. Wilson [Canada] ; Sylvain Houle [Canada] ; Antonio P. Strafella [Canada]Source :
- PloS one [ 1932-6203 ] ; 2015.
English descriptors
- KwdEn :
- Aged, Corpus Striatum (diagnostic imaging), Corpus Striatum (metabolism), Female, Genotype, Humans, Inflammation (diagnostic imaging), Inflammation (genetics), Male, Microglia (diagnostic imaging), Microglia (metabolism), Middle Aged, Neuroimaging, Parkinson Disease (diagnostic imaging), Parkinson Disease (genetics), Parkinson Disease (metabolism), Polymorphism, Genetic, Radionuclide Imaging.
- MESH :
- diagnostic imaging : Corpus Striatum, Inflammation, Microglia, Parkinson Disease.
- genetics : Inflammation, Parkinson Disease.
- metabolism : Corpus Striatum, Microglia, Parkinson Disease.
- Aged, Female, Genotype, Humans, Male, Middle Aged, Neuroimaging, Polymorphism, Genetic, Radionuclide Imaging.
Abstract
This study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation in the striatum. Neuroinflammation has been implicated as a potential mechanism for the progression of Parkinson's disease (PD). Positron Emission Tomography (PET) radioligand targeting for TSPO allows for the quantification of neuroinflammation in vivo. Based on genotype of the rs6791 polymorphism in the TSPO gene, 16 mixed-affinity binders (MABs) (8 PD and age-matched 8 healthy controls (HCs)), 16 high-affinity binders (HABs) (8 PD and age-matched 8 HCs) and 4 low-affinity binders (LABs) (3 PD and 1 HCs) were identified. Total distribution volume (VT) values in the striatum were derived from a two-tissue compartment model with arterial plasma as an input function. There was a significant main effect of genotype on [18F]-FEPPA VT values in the caudate nucleus (p = 0.001) and putamen (p < 0.001), but no main effect of disease or disease x genotype interaction in either ROI. In the HAB group, the percentage difference between PD and HC was 16% in both caudate nucleus and putamen; in the MAB group, it was -8% and 3%, respectively. While this PET study showed no evidence of increased striatal TSPO expression in PD patients, the current findings provide some insights on the possible interactions between rs6791 polymorphism and neuroinflammation in PD.
DOI: 10.1371/journal.pone.0138721
PubMed: 26381267
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000413
Links to Exploration step
pubmed:26381267Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.</title><author><name sortKey="Koshimori, Yuko" sort="Koshimori, Yuko" uniqKey="Koshimori Y" first="Yuko" last="Koshimori">Yuko Koshimori</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji-Hyun" last="Ko">Ji-Hyun Ko</name><affiliation wicri:level="1"><nlm:affiliation>Department of Human Anatomy and Cell Science, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Human Anatomy and Cell Science, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea></affiliation></author><author><name sortKey="Mizrahi, Romina" sort="Mizrahi, Romina" uniqKey="Mizrahi R" first="Romina" last="Mizrahi">Romina Mizrahi</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Mabrouk, Rostom" sort="Mabrouk, Rostom" uniqKey="Mabrouk R" first="Rostom" last="Mabrouk">Rostom Mabrouk</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Jacobs, Mark F" sort="Jacobs, Mark F" uniqKey="Jacobs M" first="Mark F" last="Jacobs">Mark F. Jacobs</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Christopher, Leigh" sort="Christopher, Leigh" uniqKey="Christopher L" first="Leigh" last="Christopher">Leigh Christopher</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Hamani, Clement" sort="Hamani, Clement" uniqKey="Hamani C" first="Clement" last="Hamani">Clement Hamani</name><affiliation wicri:level="1"><nlm:affiliation>Division of Neurosurgery, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurosurgery, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><nlm:affiliation>Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A" last="Wilson">Alan A. Wilson</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26381267</idno><idno type="pmid">26381267</idno><idno type="doi">10.1371/journal.pone.0138721</idno><idno type="wicri:Area/PubMed/Corpus">000413</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000413</idno><idno type="wicri:Area/PubMed/Curation">000413</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000413</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.</title><author><name sortKey="Koshimori, Yuko" sort="Koshimori, Yuko" uniqKey="Koshimori Y" first="Yuko" last="Koshimori">Yuko Koshimori</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji-Hyun" last="Ko">Ji-Hyun Ko</name><affiliation wicri:level="1"><nlm:affiliation>Department of Human Anatomy and Cell Science, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Human Anatomy and Cell Science, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea></affiliation></author><author><name sortKey="Mizrahi, Romina" sort="Mizrahi, Romina" uniqKey="Mizrahi R" first="Romina" last="Mizrahi">Romina Mizrahi</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Mabrouk, Rostom" sort="Mabrouk, Rostom" uniqKey="Mabrouk R" first="Rostom" last="Mabrouk">Rostom Mabrouk</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Jacobs, Mark F" sort="Jacobs, Mark F" uniqKey="Jacobs M" first="Mark F" last="Jacobs">Mark F. Jacobs</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Christopher, Leigh" sort="Christopher, Leigh" uniqKey="Christopher L" first="Leigh" last="Christopher">Leigh Christopher</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Hamani, Clement" sort="Hamani, Clement" uniqKey="Hamani C" first="Clement" last="Hamani">Clement Hamani</name><affiliation wicri:level="1"><nlm:affiliation>Division of Neurosurgery, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurosurgery, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><nlm:affiliation>Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A" last="Wilson">Alan A. Wilson</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name><affiliation wicri:level="1"><nlm:affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name><affiliation wicri:level="1"><nlm:affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Corpus Striatum (diagnostic imaging)</term><term>Corpus Striatum (metabolism)</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Inflammation (diagnostic imaging)</term><term>Inflammation (genetics)</term><term>Male</term><term>Microglia (diagnostic imaging)</term><term>Microglia (metabolism)</term><term>Middle Aged</term><term>Neuroimaging</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (metabolism)</term><term>Polymorphism, Genetic</term><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Corpus Striatum</term><term>Inflammation</term><term>Microglia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Inflammation</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Microglia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroimaging</term><term>Polymorphism, Genetic</term><term>Radionuclide Imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation in the striatum. Neuroinflammation has been implicated as a potential mechanism for the progression of Parkinson's disease (PD). Positron Emission Tomography (PET) radioligand targeting for TSPO allows for the quantification of neuroinflammation in vivo. Based on genotype of the rs6791 polymorphism in the TSPO gene, 16 mixed-affinity binders (MABs) (8 PD and age-matched 8 healthy controls (HCs)), 16 high-affinity binders (HABs) (8 PD and age-matched 8 HCs) and 4 low-affinity binders (LABs) (3 PD and 1 HCs) were identified. Total distribution volume (VT) values in the striatum were derived from a two-tissue compartment model with arterial plasma as an input function. There was a significant main effect of genotype on [18F]-FEPPA VT values in the caudate nucleus (p = 0.001) and putamen (p < 0.001), but no main effect of disease or disease x genotype interaction in either ROI. In the HAB group, the percentage difference between PD and HC was 16% in both caudate nucleus and putamen; in the MAB group, it was -8% and 3%, respectively. While this PET study showed no evidence of increased striatal TSPO expression in PD patients, the current findings provide some insights on the possible interactions between rs6791 polymorphism and neuroinflammation in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26381267</PMID><DateCreated><Year>2015</Year><Month>09</Month><Day>19</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.</ArticleTitle><Pagination><MedlinePgn>e0138721</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0138721</ELocationID><Abstract><AbstractText>This study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation in the striatum. Neuroinflammation has been implicated as a potential mechanism for the progression of Parkinson's disease (PD). Positron Emission Tomography (PET) radioligand targeting for TSPO allows for the quantification of neuroinflammation in vivo. Based on genotype of the rs6791 polymorphism in the TSPO gene, 16 mixed-affinity binders (MABs) (8 PD and age-matched 8 healthy controls (HCs)), 16 high-affinity binders (HABs) (8 PD and age-matched 8 HCs) and 4 low-affinity binders (LABs) (3 PD and 1 HCs) were identified. Total distribution volume (VT) values in the striatum were derived from a two-tissue compartment model with arterial plasma as an input function. There was a significant main effect of genotype on [18F]-FEPPA VT values in the caudate nucleus (p = 0.001) and putamen (p < 0.001), but no main effect of disease or disease x genotype interaction in either ROI. In the HAB group, the percentage difference between PD and HC was 16% in both caudate nucleus and putamen; in the MAB group, it was -8% and 3%, respectively. While this PET study showed no evidence of increased striatal TSPO expression in PD patients, the current findings provide some insights on the possible interactions between rs6791 polymorphism and neuroinflammation in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koshimori</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ji-Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Human Anatomy and Cell Science, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizrahi</LastName><ForeName>Romina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusjan</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabrouk</LastName><ForeName>Rostom</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Leigh</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamani</LastName><ForeName>Clement</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurosurgery, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Alan A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houle</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strafella</LastName><ForeName>Antonio P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Division of Brain, Imaging and Behaviour-Systems Neuroscience, Toronto Western Research Institute, University Hospital Network, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Morton and Gloria Shulman Movement Disorder Unit & Edmond.J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>117891-1</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>GDS-D 128684</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>INE 117891</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2008 Apr;118(1):1-17</RefSource><PMID Version="1">18374421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucl Med Biol. 2008 Apr;35(3):305-14</RefSource><PMID Version="1">18355686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 2009 Dec;150(12):5438-45</RefSource><PMID Version="1">19846611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2011 Aug;31(8):1807-16</RefSource><PMID Version="1">21522163</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5</RefSource><PMID Version="1">22008728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2012 Jun;32(6):968-72</RefSource><PMID Version="1">22472607</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Glia. 2013 Jan;61(1):10-23</RefSource><PMID Version="1">22615180</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2013 Jan;33(1):53-8</RefSource><PMID Version="1">22968319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2013 Mar;33(3):348-50</RefSource><PMID Version="1">23281426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 May;19(5):527-32</RefSource><PMID Version="1">23425503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2014 May;34(5):883-9</RefSource><PMID Version="1">24517979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2014 Jul 23;34(30):9945-50</RefSource><PMID Version="1">25057196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):438-46</RefSource><PMID Version="1">25412766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Psychiatry. 2015 Mar;72(3):268-75</RefSource><PMID Version="1">25629589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2015 Apr;30(4):552-9</RefSource><PMID Version="1">25639598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Psychiatry. 2015 Dec;20(12):1579-87</RefSource><PMID Version="1">25707397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Toxicol Pathol. 2000 Jan-Feb;28(1):28-30</RefSource><PMID Version="1">10668987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurocytol. 2000 May-Jun;29(5-6):307-26</RefSource><PMID Version="1">11424948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2002 Nov;83(3):546-55</RefSource><PMID Version="1">12390516</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neuropathol. 2003 Dec;106(6):518-26</RefSource><PMID Version="1">14513261</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2004 Mar;45(3):402-8</RefSource><PMID Version="1">15001679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1988 Aug;38(8):1285-91</RefSource><PMID Version="1">3399080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 1991 Oct 11;19(19):5444</RefSource><PMID Version="1">1681511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1994 Oct 24;180(2):147-50</RefSource><PMID Version="1">7700568</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1995 Dec 29;202(1-2):17-20</RefSource><PMID Version="1">8787820</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 1999 Jul;100(1):34-41</RefSource><PMID Version="1">10416510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2005 Feb;57(2):168-75</RefSource><PMID Version="1">15668962</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 2006 Jun 30;147(1):79-89</RefSource><PMID Version="1">16797168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2009 Jul;1791(7):646-58</RefSource><PMID Version="1">19286473</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4575151</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26381267</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0138721</ArticleId><ArticleId IdType="pii">PONE-D-15-25349</ArticleId><ArticleId IdType="pmc">PMC4575151</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000413 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000413 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26381267
|texte= Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26381267" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |